[시장보고서]세계의 골수증식성 질환(MPD) 치료제 및 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

세계의 골수증식성 질환(MPD) 치료제 및 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Myeloproliferative Disorders Drugs/Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

상품코드 : 1820645

리서치사 : Value Market Research

발행일 : 2025년 07월

페이지 정보 : 영문 149 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,920

￦ 5,818,000

PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 4,730

￦ 7,020,000

PDF & Excel (10-user License)

PDF 및 Excel 보고서를 동일 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 7,430

￦ 11,027,000

PDF & Excel (Corporate User License)

PDF 및 Excel 보고서를 동일 기업 내 모든 사용자가 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 골수증식성 질환(MPD) 치료제 및 치료 시장은 2025-2033년 연평균 성장률(CAGR) 3.48%로 성장할 것으로 예측되어 현저한 확대가 전망되고 있습니다. 시장 분석에 따르면 시장 규모는 2024년 101억 6,000만 달러에서 2033년 말까지 138억 2,000만 달러에 이를 것으로 예측됩니다.

세계의 골수증식성 질환(MPD) 치료제 및 치료 시장은 진단률 상승과 표적 치료의 진보에 견인되어 성장할 것으로 보입니다. JAK 억제제와 인터페론 제제와 같은 새로운 약물은 질병 관리 및 환자 결과를 개선합니다. 향후 개발에서는 병용 요법, 맞춤형 의료 접근법, 조기 발견 및 치료 모니터링을 위한 새로운 바이오마커가 주목됩니다.

또한 임상시험 확대와 규제 당국의 승인으로 혁신적인 치료법 시장 진입이 가속화되고 있습니다. 환자 지원 및 계발 프로그램의 상승으로 진단과 어드히어런스가 향상되었습니다. 유전체 프로파일링과 디지털 건강 도구의 발전은 정밀의료를 촉진하고 있습니다. 혈액 종양학이 발전함에 따라 MPD 치료제 및 치료 시장은 혁신을 계속하고 효과적이고 개별화된 보다 안전한 치료 옵션을 제공해 나갈 것입니다.

지역별 전망
서문
북미의 매출 분석
- 개요, 분석 및 예측
- 북미 : 부문별
- 북미 국가별
- 미국
- 캐나다
- 멕시코
유럽의 매출 분석
- 개요, 분석 및 예측
- 유럽 : 부문별
- 유럽 국가별
- 영국
- 프랑스
- 독일
- 이탈리아
- 러시아
- 기타 유럽
아시아태평양의 매출 분석
- 개요, 분석 및 예측
- 아시아태평양 : 부문별
- 아시아태평양 국가별
- 중국
- 인도
- 일본
- 한국
- 호주
- 동남아시아
- 기타 아시아태평양
라틴아메리카의 매출 분석
- 개요, 분석 및 예측
- 라틴아메리카 : 부문별
- 라틴아메리카 국가별
- 브라질
- 아르헨티나
- 페루
- 칠레
- 기타 라틴아메리카
중동 및 아프리카의 매출 분석
- 개요, 분석 및 예측
- 중동 및 아프리카 : 부문별
- 중동 및 아프리카 국가별 일람
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카

제10장 골수증식성 질환(MPD) 치료제 및 치료 기업 경쟁 구도

골수증식성 질환(MPD) 치료제 및 치료 시장의 경쟁
제휴, 협력 및 합의
합병 및 인수
신제품 출시
기타 개발

제11장 기업 프로파일

주요 기업의 시장 점유율 분석
시장 집중도
AbbVie Inc.
Bristol-Myers Squibb Company
Eli Lilly And Company
GlaxoSmithKline Plc(GSK)
GL Pharma GmbH Incyte Corporation
Janssen Biotech Inc.(Johnson & Johnson)
MorphoSys AG
Mylan NV(Viatris)
Novartis Pharmaceuticals Corporation(Novartis AG)
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd

AJY

영문 목차

영문목차

Global Myeloproliferative Disorders Drugs/Treatment Market is anticipated to experience remarkable expansion, with a projected Compound Annual Growth Rate (CAGR) of 3.48% from 2025 to 2033. According to the market analysis, the market size is forecasted to reach USD 13.82 Billion by the end of 2033, up from USD 10.16 Billion in 2024.

The global myeloproliferative disorders (MPD) drugs and treatment market is set for growth driven by increasing diagnosis rates and advancements in targeted therapies. Novel agents such as JAK inhibitors and interferon formulations are improving disease management and patient outcomes. Future developments will focus on combination therapies, personalized medicine approaches, and novel biomarkers for early detection and treatment monitoring.

Additionally, expanding clinical trials and regulatory approvals are accelerating market availability of innovative treatments. The rise of patient advocacy and awareness programs is enhancing diagnosis and adherence. Advances in genomic profiling and digital health tools are facilitating precision medicine. As hematologic oncology evolves, the MPD drugs and treatment market will continue to innovate, delivering effective, tailored, and safer therapeutic options.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Myeloproliferative Disorders Drugs/Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disorder Type

Philadelphia Chromosome-Positive (Ph+) CML
Philadelphia Chromosome-Negative (Ph-) MPNs
Polycythemia Vera
Essential Thrombocythemia
Myelofibrosis
Other Disorder Types

By Drug Class

Tyrosine Kinase Inhibitors
Janus Kinase Inhibitors
Hydroxyurea
Other Drug Classes

By Route Of Administration

Oral
Injectable

By End-Use

Hospitals
Specialty Clinics
Other End-Users
List of Companies Profiled in the report
AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc (GSK), GL Pharma GmbH Incyte Corporation, Janssen Biotech Inc. (Johnson & Johnson), MorphoSys AG, Mylan N.V. (Viatris), Novartis Pharmaceuticals Corporation (Novartis AG), Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Disorder Type
- 3.7.2 Market Attractiveness Analysis By Drug Class
- 3.7.3 Market Attractiveness Analysis By Route Of Administration
- 3.7.4 Market Attractiveness Analysis By End-Use
- 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY DISORDER TYPE

5.1. Overview By Disorder Type
5.2. Historical and Forecast Data Analysis By Disorder Type
5.3. Philadelphia Chromosome-Positive (Ph+) CML Historic and Forecast Sales By Regions
5.4. Philadelphia Chromosome-Negative (Ph-) MPNs Historic and Forecast Sales By Regions
5.5. Polycythemia Vera Historic and Forecast Sales By Regions
5.6. Essential Thrombocythemia Historic and Forecast Sales By Regions
5.7. Myelofibrosis Historic and Forecast Sales By Regions
5.8. Other Disorder Types Historic and Forecast Sales By Regions

6. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY DRUG CLASS

6.1. Overview By Drug Class
6.2. Historical and Forecast Data Analysis By Drug Class
6.3. Tyrosine Kinase Inhibitors Historic and Forecast Sales By Regions
6.4. Janus Kinase Inhibitors Historic and Forecast Sales By Regions
6.5. Hydroxyurea Historic and Forecast Sales By Regions
6.6. Other Drug Classes Historic and Forecast Sales By Regions

7. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1. Overview By Route Of Administration
7.2. Historical and Forecast Data Analysis By Route Of Administration
7.3. Oral Historic and Forecast Sales By Regions
7.4. Injectable Historic and Forecast Sales By Regions

8. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY END-USE

8.1. Overview By End-Use
8.2. Historical and Forecast Data Analysis By End-Use
8.3. Hospitals Historic and Forecast Sales By Regions
8.4. Specialty Clinics Historic and Forecast Sales By Regions
8.5. Other End-Users Historic and Forecast Sales By Regions

9. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT COMPANIES

10.1. Myeloproliferative Disorders Drugs/Treatment Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. AbbVie Inc.
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Bristol-Myers Squibb Company
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Eli Lilly And Company
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. GlaxoSmithKline Plc (GSK)
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. GL Pharma GmbH Incyte Corporation
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Janssen Biotech Inc. (Johnson & Johnson)
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. MorphoSys AG
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Mylan N.V. (Viatris)
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Novartis Pharmaceuticals Corporation (Novartis AG)
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Takeda Pharmaceutical Company Limited
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. Teva Pharmaceutical Industries Ltd
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

한글목차

목차

제1장 서문

제2장 주요 요약

제3장 골수 증식성 질환 치료제 및 치료 : 산업 분석

제4장 밸류체인 분석

제5장 세계의 골수증식성 질환(MPD) 치료제 및 치료 시장 분석 : 질환 유형별

제6장 세계의 골수증식성 질환(MPD) 치료제 및 치료 시장 분석 : 약제 클래스별

제7장 세계의 골수증식성 질환(MPD) 치료제 및 치료 시장 분석 : 투여 경로별

제8장 세계의 골수증식성 질환(MPD) 치료제 및 치료 시장 분석 : 최종 용도별

제9장 세계의 골수증식성 질환(MPD) 치료제 및 치료 시장 분석 : 지역별